ZURA Zura Bio Ltd - Ordinary Shares - Class A
934
$6.05
$0.05
(0.83%)
| Watchers | 934 |
| 52-Wk Low | $2.00 |
| 52-Wk High | $13.00 |
| Market Cap | $385.29M |
| Volume | 439,335.00 |
| 52-Wk High | $13.00 |
| 52-Wk Low | $2.00 |
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire • 11 days ago
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its...
Share to Feed
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it...
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Zura Bio Ltd (ZURA) Aligns with EPS Projections, Net Loss Increases Significantly from Previous YearRelated Stocks: ZURA...
An announcement from Zura Bio (ZURA) is now available. ZURA is set to experience a change in leadership as Robert Lisicki takes over as CEO from th...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the fourth quarter of 2023.
The post ZURA Stock...
Zura Bio Limited (Nasdaq: ZURA) (Zura Bio) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members...